In a recent report, a Goldman analyst asked clients: “Is curing patients a sustainable business model?” Salveen Richter wrote: “The potential to deliver ‘one-shot cures’ is one of the most attractive aspects of gene therapy. … However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies. … While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”